Gene therapy for tuberous sclerosis
US-2024343768-A1 · Oct 17, 2024 · US
Synergistic combination of neuronal viability factors and uses thereof
US10668129B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10668129-B2 |
| Application number | US-201615576027-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2016 |
| Priority date | May 21, 2015 |
| Publication date | Jun 2, 2020 |
| Grant date | Jun 2, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. An expression vector comprising a first nucleic acid encoding a short isoform of the NXNL1 gene, Rod-derived Cone Viability Factor (RdCVF) and a second nucleic acid encoding a long isoform of the NXNL1 gene, RdCVFL, wherein said expression vector is an adeno-associated virus (AAV) and wherein said short isoform of RdCVF is the short isoform of human RdCVF and wherein said long isoform is the long isoform of human RdCVFL. 2. An expression vector according to claim 1 wherein said AAV is selected in the group consisting of AAV2, AAV9 and AAV7m8. 3. A method for treating a patient suffering from a retinal degenerative disease comprising the step of administering to said patient a therapeutically effective amount of an expression vector according to claim 1 . 4. A method according to claim 3 , wherein said retinal degenerative disease is retinitis pigmentosa. 5. A method according to claim 3 , wherein said expression vector is administered by intravenous injection or by intravitreal injection.
Assignees
Inventors
Classifications
Demonstrated in vivo effect · CPC title
from mammals · CPC title
Ophthalmic agents · CPC title
- A61K38/1709Primary
from mammals · CPC title
Viral vectors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10668129B2 cover?
- The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Pierre Et Marie Curie Paris 6, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).